Search - tctmd.com

Displaying 21 - 40 of 42

Sort: Relevancy | Date

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

Todd Neale

September 07, 2017

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

Todd Neale

August 29, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

November 11, 2016

News Daily News

比伐卢定和普通肝素对有无 ST 段抬高的 ACS 患者没有任何差异：MATRIX

Shelley Wood

October 03, 2016

News Daily News

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Shelley Wood

October 03, 2016

News Daily News

MATRIX: No Hay Diferencias entre Bivalirudina y Heparina No Fraccionada en Pacientes SCA Con o Sin Elevación del Segmento ST

Shelley Wood

October 03, 2016

News Daily News

Another Meta-Analysis Supports Prolonged Bivalirudin Use in STEMI, but Is Contemporary PCI Reflected?

Yael L. Maxwell

July 27, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

News Daily News

Signs of Cardioprotection Seen in Acute STEMI Patients Receiving IV Beta-blocker Post-PCI

Caitlin E. Cox

February 03, 2016

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Daily News

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

Yael L. Maxwell

January 12, 2015

News Conference News TCT 2014

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

September 14, 2014

News Daily News

Majority of US Patients Still Discharged on High-Dose Aspirin After Acute MI

Todd Neale

August 20, 2014

News Daily News

Radial PCI Plus Bivalirudin Effective in Lowering Bleeding Risk

L.A. McKeown

August 19, 2013

News Daily News

Bivalirudin Shows Advantage Over GPIs—But Not Heparin Alone—in STEMI Patients

L.A. McKeown

November 28, 2012

News Daily News

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

Yael L. Maxwell

October 13, 2011

News Daily News

BARC: New Bleeding Definitions Aim to Standardize Trial Endpoints

L.A. McKeown

June 17, 2011

Advertisement

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

P2Y12 Inhibitor Pretreatment Questioned in STEMI

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

比伐卢定和普通肝素对有无 ST 段抬高的 ACS 患者没有任何差异：MATRIX

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

MATRIX: No Hay Diferencias entre Bivalirudina y Heparina No Fraccionada en Pacientes SCA Con o Sin Elevación del Segmento ST

Another Meta-Analysis Supports Prolonged Bivalirudin Use in STEMI, but Is Contemporary PCI Reflected?

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Signs of Cardioprotection Seen in Acute STEMI Patients Receiving IV Beta-blocker Post-PCI

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

Majority of US Patients Still Discharged on High-Dose Aspirin After Acute MI

Radial PCI Plus Bivalirudin Effective in Lowering Bleeding Risk

Bivalirudin Shows Advantage Over GPIs—But Not Heparin Alone—in STEMI Patients

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

BARC: New Bleeding Definitions Aim to Standardize Trial Endpoints

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content